TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload
Brief Summary: CICL670A2209: This study will evaluate the safety and efficacy of deferasirox in non-transfusion dependent thalassemia patients with iron overload. Patients will be treated either with active treatment (deferasirox) or placebo for 12 months (core study phase). Patients who complete the core study phase will be offered to continue their study with the active treatment (deferasirox) in a 12 months extension phase. During the core and extension, the effects of treatment on iron overload in the liver will be evaluated using magnetic resonance imaging (MRI) assessments.

CICL670A2209E1: A one-year open-label extension to a randomized, double-blind, placebo-controlled, phase II study to evaluate efficacy and safety of deferasirox in non-transfusion dependent thalassemia patients with iron overload (Thalassa).


Options:
A: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox
B: Arm Label: 5 mg/kg/day deferasirox; Type: EXPERIMENTAL; Interventions: Drug: deferasirox, Drug: placebo | Arm Label: 10 mg/kg/day deferasirox; Type: EXPERIMENTAL; Interventions: Drug: deferasirox, Drug: placebo | Arm Label: 5 mg/kg/day placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 10 mg/kg/day placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: deferasirox; Assigned to Arm(s): 10 mg/kg/day deferasirox, 5 mg/kg/day deferasirox | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 10 mg/kg/day deferasirox, 10 mg/kg/day placebo, 5 mg/kg/day deferasirox, 5 mg/kg/day placebo
C: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
D: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy
Brief Summary: The investigators main hypothesis is that the stone free rate will be much higher (95%) in patients treated with PCNL than patients treated with ESWL where stone free rate is (60%) to determine which treatment is safe and prevent less stone recurrence.


Options:
A: Arm Label: Group 1; Type: OTHER; Interventions: Procedure: Super-Mini Percutaneous Nephrolithotomy | Arm Label: Group 2; Type: OTHER; Interventions: Procedure: Retrograde Intrarenal Surgery | Intervention Type: PROCEDURE; Name: Super-Mini Percutaneous Nephrolithotomy; Assigned to Arm(s): Group 1 | Intervention Type: PROCEDURE; Name: Retrograde Intrarenal Surgery; Assigned to Arm(s): Group 2
B: Arm Label: Microperc surgery; Type: EXPERIMENTAL; Interventions: Procedure: Microperc surgery | Arm Label: FURS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: FURS | Intervention Type: PROCEDURE; Name: Microperc surgery; Assigned to Arm(s): Microperc surgery | Intervention Type: PROCEDURE; Name: FURS; Assigned to Arm(s): FURS
C: Arm Label: 1 ESWL; Type: N/A; Interventions: N/A | Arm Label: 2 PCNL; Type: N/A; Interventions: N/A
D: Arm Label: PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PCNL | Arm Label: mini-PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mini-PCNL | Arm Label: RIRS Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIRS | Intervention Type: PROCEDURE; Name: PCNL; Assigned to Arm(s): PCNL Group | Intervention Type: PROCEDURE; Name: mini-PCNL; Assigned to Arm(s): mini-PCNL Group | Intervention Type: PROCEDURE; Name: RIRS; Assigned to Arm(s): RIRS Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Activating Collaborative CIS Support Via Targeted Provider Mailing
Brief Summary: RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their follow-up colposcopy appointment.

PURPOSE: This randomized clinical trial is studying a personalized letter with Cancer Information Service support to see how well it works compared with a standard reminder letter in women scheduled for colposcopy after an abnormal Pap test.


Options:
A: Arm Label: CHWs facilitated Self-Sampling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CHW and Self-sampling for Cervical Cancer | Arm Label: Mailed Self-Sampler; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mailed Self Sampler | Intervention Type: BEHAVIORAL; Name: CHW and Self-sampling for Cervical Cancer; Assigned to Arm(s): CHWs facilitated Self-Sampling | Intervention Type: BEHAVIORAL; Name: Mailed Self Sampler; Assigned to Arm(s): Mailed Self-Sampler
B: Arm Label: Usual Care mailing intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care mailing intervention | Arm Label: CIS support mailing intervention; Type: EXPERIMENTAL; Interventions: Other: CIS support mailing intervention | Intervention Type: OTHER; Name: Usual care mailing intervention; Assigned to Arm(s): Usual Care mailing intervention | Intervention Type: OTHER; Name: CIS support mailing intervention; Assigned to Arm(s): CIS support mailing intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity Information (DVD); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DVD | Arm Label: High Intensity Information (Promotora); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Promotora | Intervention Type: BEHAVIORAL; Name: DVD; Assigned to Arm(s): Low Intensity Information (DVD) | Intervention Type: BEHAVIORAL; Name: Promotora; Assigned to Arm(s): High Intensity Information (Promotora)
D: Arm Label: Usual care / opportunistic screening; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Letter and informational sheet; Type: EXPERIMENTAL; Interventions: Other: Letter and informational sheet | Arm Label: Email; Type: EXPERIMENTAL; Interventions: Other: Email | Arm Label: Phone; Type: EXPERIMENTAL; Interventions: Other: Phone | Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Other: Multimodal | Intervention Type: OTHER; Name: Letter and informational sheet; Assigned to Arm(s): Letter and informational sheet | Intervention Type: OTHER; Name: Email; Assigned to Arm(s): Email | Intervention Type: OTHER; Name: Phone; Assigned to Arm(s): Phone | Intervention Type: OTHER; Name: Multimodal; Assigned to Arm(s): Multimodal

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Coping Skills Training in Heart Failure: Outcomes and Mechanisms
Brief Summary: This study will evaluate whether heart failure patients receiving a 16 week telephone delivered, intervention using cognitive behavior therapy to facilitate self-management of heart failure will have better clinical outcomes than heart failure patients receiving a 16 week heart failure education intervention via telephone.


Options:
A: Arm Label: Coping Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Coping skills training | Arm Label: Educational Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping skills training | Intervention Type: BEHAVIORAL; Name: Coping skills training; Assigned to Arm(s): Coping Skills Training, Educational Control
B: Arm Label: Web-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web-based multifactorial intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: Behavioral: web-based multifactorial intervention | Intervention Type: BEHAVIORAL; Name: web-based multifactorial intervention; Assigned to Arm(s): Usual care, Web-based behavioral intervention
C: Arm Label: Clinical Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CBT + WBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT in combination with WBT and life style modification | Intervention Type: BEHAVIORAL; Name: CBT in combination with WBT and life style modification; Assigned to Arm(s): CBT + WBT
D: Arm Label: real-time, face-to-face, video-conferenced CBT (vcCBT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online cognitive behavioral therapy | Arm Label: self-administered internet-based CBT (iCBT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online cognitive behavioral therapy | Intervention Type: BEHAVIORAL; Name: Online cognitive behavioral therapy; Assigned to Arm(s): real-time, face-to-face, video-conferenced CBT (vcCBT), self-administered internet-based CBT (iCBT)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Brief Summary: The purpose of this study is to evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children aged 2-6 years as measured by the change from baseline in the Autism Diagnostic Observation Schedule (ADOS) Composite Total scores compared to placebo at 6 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2 Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3 Aripiprazole + D-cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole, Drug: D-cycloserine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 Aripiprazole, 3 Aripiprazole + D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 3 Aripiprazole + D-cycloserine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Brief Summary: The purpose of this study is to evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children aged 2-6 years as measured by the change from baseline in the Autism Diagnostic Observation Schedule (ADOS) Composite Total scores compared to placebo at 6 months.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Brief Summary: The purpose of this study is to evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children aged 2-6 years as measured by the change from baseline in the Autism Diagnostic Observation Schedule (ADOS) Composite Total scores compared to placebo at 6 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline
C: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supplemental Postoperative Oxygen and the Risk of Surgical Wound Infection in a Vascular Surgery Population: A Randomized Controlled Trial
Brief Summary: The purpose of this study was to test the hypothesis that supplemental postoperative oxygen reduces the risk of surgical wound infection in patients following lower limb vascular surgery.


Options:
A: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A
B: Arm Label: 70% Nitrous Oxide; Type: OTHER; Interventions: Other: Nitrous Oxide | Arm Label: No Nitrous Oxide; Type: OTHER; Interventions: Other: No Nitrous Oxide | Intervention Type: OTHER; Name: Nitrous Oxide; Assigned to Arm(s): 70% Nitrous Oxide | Intervention Type: OTHER; Name: No Nitrous Oxide; Assigned to Arm(s): No Nitrous Oxide
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental postoperative oxygen | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: supplemental postoperative oxygen; Assigned to Arm(s): 1
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen by mask | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen by mask | Intervention Type: OTHER; Name: Oxygen by mask; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Oxygen by mask; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis
Brief Summary: The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis (AS) and previous failure to usual practice therapies in Spain.


Options:
A: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept/placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: etanercept/placebo; Assigned to Arm(s): 2
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulphasalazine (SSZ) | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: sulphasalazine (SSZ); Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), on Asthma Control in Adults With Uncontrolled, Moderate-to-severe, Persistent Asthma
Brief Summary: This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled, moderate-to-severe, persistent asthma.


Options:
A: Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab SC, Placebo SC
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg
C: Arm Label: 1; Type: N/A; Interventions: N/A
D: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), on Asthma Control in Adults With Uncontrolled, Moderate-to-severe, Persistent Asthma
Brief Summary: This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled, moderate-to-severe, persistent asthma.


Options:
A: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mepolizumab Arm; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab Arm

Answer: B